Novartis AG ADR (NVS)vsVarex Imaging Corp (VREX)
NVS
Novartis AG ADR
$145.46
+1.32%
HEALTHCARE · Cap: $271.25B
VREX
Varex Imaging Corp
$18.45
-0.11%
HEALTHCARE · Cap: $779.32M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 6454% more annual revenue ($56.69B vs $865.00M). NVS leads profitability with a 22.5% profit margin vs 2.6%. NVS appears more attractively valued with a PEG of 3.31. VREX earns a higher WallStSmart Score of 55/100 (C-).
NVS
Buy51
out of 100
Grade: C-
VREX
Buy55
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-53.7%
Fair Value
$93.40
Current Price
$145.46
$52.06 premium
Margin of Safety
+14.7%
Fair Value
$15.95
Current Price
$18.45
$2.50 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.6%
Keeps 23 of every $100 in revenue as profit
Generating 5.6B in free cash flow
Earnings expanding 453.4% YoY
Reasonable price relative to book value
Areas to Watch
0.8% revenue growth
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Premium valuation, high expectations priced in
3.7% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.
Bull Case : VREX
The strongest argument for VREX centers on EPS Growth, Price/Book.
Bear Case : NVS
The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.
Bear Case : VREX
The primary concerns for VREX are P/E Ratio, Revenue Growth, Altman Z-Score. Thin 2.6% margins leave little buffer for downturns.
Key Dynamics to Monitor
VREX carries more volatility with a beta of 0.96 — expect wider price swings.
VREX is growing revenue faster at 3.7% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
VREX scores higher overall (55/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Varex Imaging Corp
HEALTHCARE · MEDICAL DEVICES · USA
Varex Imaging Corporation designs and manufactures X-ray imaging components. The company is headquartered in Salt Lake City, Utah.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?